Karius: Funding, Investors & Team (Oct 2026)
Karius is a biotech company that specializes in providing genomic information on infectious diseases through a non-invasive liquid biopsy. Their Karius Test aids healthcare providers in quickly determining the most effective treatment options. With the ability to analyze a patient's microbial makeup from just one blood sample, Karius aims to reduce the impact of infectious diseases on global health. The company's laboratory is certified by CLIA and accredited by CAP to conduct advanced clinical testing.
Karius has raised $265M across 2 funding rounds on record, the most recent a Series C of $100M announced in May 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Karius Company Profile and Key Stats
Latest funding round on record: May 2024.
Karius Funding Rounds
Karius raised $165M in an undisclosed round announced in Feb 2020.
4.3 years later, a Series C of $100M was announced in May 2024.
Karius Founders and Leadership Team
Contact details for the Karius team: 1 of 1 has an email address on file.
Start 14-day free trial →Karius Funding Compared to Other Biotechnology Startups
Karius' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Karius in Biotechnology and Redwood City
Companies Similar to Karius
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Karius Funding FAQs
What does Karius do?
Karius is a biotech company that specializes in providing genomic information on infectious diseases through a non-invasive liquid biopsy. Their Karius Test aids healthcare providers in quickly determining the most effective treatment options. With the ability to analyze a patient's microbial makeup from just one blood sample, Karius aims to reduce the impact of infectious diseases on global health. The company's laboratory is certified by CLIA and accredited by CAP to conduct advanced clinical testing.
How much funding has Karius raised?
Karius has raised $265M across 2 rounds on record. The most recent is a Series C of $100M announced in May 2024.
When did Karius last raise funding?
Karius' most recent funding round on record is a Series C of $100M, announced in May 2024.
Who founded Karius?
FundedIQ lists Mickey Kertesz (Founder) at Karius.
Where is Karius headquartered?
Karius is based in Redwood City, California, United States.
How many employees does Karius have?
Karius is in the 101-250 employee band.
How does Karius' funding compare to other Biotechnology startups?
Karius' latest round of $100M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Karius Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Karius is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.